Once-Weekly Exenatide for Type 2 Diabetes

In January 2012, a formulation of exenatide that requires only a once-weekly injection (Bydureon) was approved by the FDA. In this manufacturer-funded, placebo-controlled study, about 800 patients with type 2 diabetes (mean glycosylated hemoglobin [HbA1c], 8.5%) were randomized to …